Basilea initiates targeted biomarker-driven phase 2 study with lisavanbulin in patients with brain cancer
Basel, Switzerland, September 29, 2020
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has initiated a phase 2 expansion study with its tumor checkpoint controller, lisavanbulin, in patients with recurrent glioblastoma multiforme (GBM), whose tumor has tested positive for the potential response-predictive biomarker EB1 (end-binding protein 1).1
Glioblastoma is the most common type of primary brain cancer and one of the most lethal types of cancer.2 In the open-label study, patients will receive once daily oral lisavanbulin. To identify patients with EB1-positive glioblastoma, a tissue screening program has been implemented using a CE-marked immunohistochemistry clinical trial assay developed for the lisavanbulin program.
Dr. Marc Engelhardt, Chief Medical Officer, said: “The initiation of the phase 2 study is an important step for us to validate our hypothesis that lisavanbulin may be developed for a targeted patient population based on a patient-selection biomarker. We expect interim results in the first half of 2021 and the outcome of this study will define the next development steps for lisavanbulin, including potentially expanding into other tumor types using a biomarker-driven approach.”
EB1 was selected by Basilea as a potential response-predictive biomarker for lisavanbulin based on preclinical studies in glioblastoma models and initial clinical signals from earlier clinical studies. One glioblastoma patient in the phase 1 portion of the current study, whose tumor tissue was strongly positive for EB1, was reported as an exceptional long-lasting responder.3 This patient continues on treatment for more than two years now and shows a more than 80% area reduction of the brain tumor.
About lisavanbulin (BAL101553)
Basilea's oncology drug candidate lisavanbulin (BAL101553, the prodrug of BAL27862)4 is being developed as a potential therapy for diverse cancers.1, 5, 6 In preclinical studies, lisavanbulin demonstrated in-vitro and in-vivo activity against diverse treatment-resistant cancer models, including tumors refractory to conventional approved therapeutics and radiotherapy.7,8, 9 Lisavanbulin efficiently distributes to the brain, with anticancer activity in glioblastoma models.10, 11, 12 In preclinical studies, end-binding protein 1 (EB1) was identified as a potential response-predictive biomarker in glioblastoma models.12 The active moiety BAL27862 binds to the colchicine site of tubulin, with distinct effects on microtubule organization,13 resulting in the activation of the "spindle assembly checkpoint" which promotes tumor cell death.14
Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
|Peer Nils Schröder, PhD|
Head of Corporate Communications & Investor Relations
|Phone||+41 61 606 1102|
This press release can be downloaded from www.basilea.com.
- ClinicalTrials.gov identifier: NCT02490800
- B. M. Alexander, T. F. Cloughesy. Adult Glioblastoma. Journal of Clinical Oncology 2017 (35), 2402-2409
- J. S. Lopez, R. Kristeleit, R. Rulach et al. Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma. Journal of Clinical Oncology 2019, 37, 15 supplement, 2025
- J. Pohlmann, F. Bachmann, A. Schmitt-Hoffmann et al. BAL101553: An optimized prodrug of the microtubule destabilizer BAL27862 with superior antitumor activity. American Association for Cancer Research (AACR) annual meeting 2011, abstract 1347; Cancer Research 2011, 71 (8 supplement)
- ClinicalTrials.gov identifier: NCT03250299
- ClinicalTrials.gov identifier: NCT02895360
- A. Sharmq, A. Broggini-Tenzer, V. Vuong et al. The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models. Radiotherapy Oncology 2017 (124), 433-438
- G. E. Duran, H. Lane, F. Bachmann et al. In vitro activity of the novel tubulin active agent BAL27862 in MDR1(+) and MDR1(-) human breast and ovarian cancer variants selected for resistance to taxanes. American Association for Cancer Research (AACR) annual meeting 2010, abstract 4412; Cancer Research 2010, 70 (8 supplement)
- F. Bachmann, K. Burger, G. E. Duran et al. BAL101553 (prodrug of BAL27862): A unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab. American Association for Cancer Research (AACR) annual meeting 2014, abstract 831; Cancer Research 2014, 74 (19 supplement)
- A. Schmitt-Hoffmann, D. Klauer, K. Gebhardt et al. BAL27862: a unique microtubule-targeted agent with a potential for the treatment of human brain tumors. AACR-NCI-EORTC conference 2009, abstract C233; Molecular Cancer Therapeutics 2009, 8 (12 supplement)
- A. C. Mladek, J. L. Pokorny, H. Lane et al. The novel tubulin-binding 'tumor checkpoint controller' BAL101553 has anti-cancer activity alone and in combination treatments across a panel of GBM patient-derived xenografts. American Association for Cancer Research (AACR) annual meeting 2016, abstract 4781; Cancer Research 2016, 76 (14 supplement)
- R. Bergès, A. Tchoghandjian, S. Honoré et al. The novel tubulin-binding checkpoint activator BAL101553 inhibits EB1-dependent migration and invasion and promotes differentiation of glioblastoma stem-like cells. Molecular Cancer Therapeutics 2016 (15), 2740-2749
- A. E. Prota, F. Danel, F. Bachmann et al. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization. Journal of Molecular Biology 2014 (426), 1848-1860
- F. Bachmann, K. Burger, H. Lane. BAL101553 (prodrug of BAL27862): the spindle assembly checkpoint is required for anticancer activity. American Association for Cancer Research (AACR) annual meeting 2015, abstract 3789; Cancer Research 2015, 75 (15 supplement)
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Galapagos increases share capital through subscription right exercises4.12.2020 22:01:00 CET | Press release
Mechelen, Belgium; 4 December 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 70,925 new ordinary shares on 4 December 2020, for a total capital increase (including issuance premium) of €2,615,857.50. Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15,000 subscription rights. Three other management board members exercised an aggregate number of 15,000 subscription rights. In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €353,819,443.97, the total number of securities conferring voting rights amounts to 65,411,767, which is also the total
REC Silicon - Approval and publication of prospectus4.12.2020 20:39:33 CET | Press release
Lysaker, 4 December 2020. Reference is made to the stock exchange announcements by REC Silicon ASA (the "Company") on 14 October 2020 and 15 October 2020 regarding the successful completion of a private placement raising gross proceeds of approximately NOK 1,000 million (the "Private Placement"). A prospectus for listing of the 92,592,592 new shares in the Company issued in connection with the Private Placement was approved by the Financial Supervisory Authority of Norway on 4 December 2020. The prospectus and a summary of the prospectus will be available at the Company's website www.recsilicon.com. For further information, please contact: James A. May II, Chief Financial Officer Phone: +1 509 989 1023 Email: email@example.com Nils O. Kjerstad IR Contact Phone: +47 9135 6659 Email: firstname.lastname@example.org About the Company: REC Silicon is a leading producer of advanced silicon materials, delivering high-purity polysilicon and silicon gas to the solar and electronics industries wor
Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD4.12.2020 18:30:00 CET | Press release
Results of REACH3trial also demonstratesignificant improvements in failure-free survival (FFS) and patient-reported symptoms1Chronic graft-versus-host disease (GvHD) is a life-threateningcomplication ofstem cell transplants and half of patients become steroid refractory/dependent2,3Findingsfrom the study were presented at ASH 2020,and complement previouslyreported positive results for Jakavi in acute GvHD; data to be submitted to ex-U.S. health authorities4 Basel, December4, 2020 — Detailed results from the pivotal Phase III REACH3 study demonstrate Jakavi® (ruxolitinib) significantly improved outcomes across a range of efficacy measures in patients with steroid-refractory/dependent chronic graft-versus-host disease (GvHD) compared to best available therapy (BAT)1. The results of REACH3, the first successful, randomized Phase III trial in chronic GvHD, were presented today during the 62nd American Society of Hematology Annual Meeting & Exposition (ASH). REACH3 is jointly sponsored by N
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS4.12.2020 16:20:00 CET | Press release
Bid procedure, 2020-12-10BondsDANSKE HYPOTEK AB: 2312. SE0011116474. 2023-12-20 LANSFORSAKRINGAR HYPOTEK: 516, SE0009190390, 2023-09-20 NORDEA HYPOTEK AB: 5533, SE0010442731, 2023-09-20 SKANDINAVISKA ENSKILDA: 576, SE0010049841, 2023-12-20 SWEDISH COVERED BOND: 144., SE0011167428, 2023-06-21 STADSHYPOTEK AB: 1588, SE0011063015, 2024-03-01 SWEDBANK HYPOTEK AB: 193, SE0011089622, 2023-12-20 Bid date2020-12-10Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)2312: 300 mln SEK +/-150 mln SEK 516: 600 mln SEK +/-300 mln SEK 5533: 1000 mln SEK +/-500 mln SEK 576: 800 mln SEK +/-400 mln SEK 144.: 600 mln SEK +/-300 mln SEK 1588: 1200 mln SEK +/-600 mln SEK 193: 1000 mln SEK +/-500 mln SEK Maximum 5500 mln in totalHighest permitted bid volume (corresponding nominal amount)2312: 300 mln SEK per bid 516: 600 mln SEK per bid 5533: 1000 mln SEK per bid 576: 800 mln SEK per bid 144.: 600 mln SEK per bid 1588: 1200 mln SEK per bid 193: 1000 mln SEK per bid
CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS4.12.2020 16:20:00 CET | Press release
Bid procedure, 2020-12-08BondsKOMMUNINVEST I SVERIGE: 2311. SE0010948240. 2023-11-13 KOMMUNINVEST I SVERIGE: 2611, SE0012569572, 2026-11-12 BidsBids on interest and volume are entered via Bloomberg Bond Auction SystemBid date2020-12-08Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)2311: 1000 mln SEK +/-250 mln SEK 2611: 1000 mln SEK +/-250 mln SEK Maximum 2000 mln in totalHighest permitted bid volume (corresponding nominal amount)2311: 1000 mln SEK per bid 2611: 1000 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNo later than 11.10 (CET/CEST) on the Bid dateDelivery and payment date2020-12-10Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383General Terms and ConditionsGeneral Terms and Conditions General Terms and Conditions för the Riksbank’s Purchases of Bonds via Bid Procedure 2020:3. dated 20 November 2020
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS4.12.2020 16:20:00 CET | Press release
Bid procedure, 2020-12-11BondsSWEDISH GOVERNMENT: 1060. SE0009496367. 2028-05-12 SWEDISH GOVERNMENT: 1062, SE0013935319, 2031-05-12 Bid date2020-12-11Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1060: 1500 mln SEK +/-250 mln SEK 1062: 1500 mln SEK +/-250 mln SEK Maximum 3000 mln in totalHighest permitted bid volume (corresponding nominal amount)1060: 1500 mln SEK per bid 1062: 1500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNo later than 10.10 (CET/CEST) on the Bid dateDelivery and payment date2020-12-15Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2020-12-04 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Com
Klövern offentliggör preliminärt utfall i företrädesemission4.12.2020 16:00:00 CET | Pressemelding
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN, AUSTRALIEN, HONGKONG, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN ÅTGÄRD INTE SKULLE VARA FÖRENLIG MED TILLÄMPLIGA LAGAR OCH FÖRESKRIFTER. YTTERLIGARE RESTRIKTIONER ÄR TILLÄMPLIGA. SE AVSNITTET ”VIKTIG INFORMATION” I SLUTET AV DETTA PRESSMEDDELANDE. Teckningsperioden i Klövern AB:s (publ) (”Klövern” eller ”Bolaget”) företrädesemission avslutades den 3 december 2020. Det preliminära utfallet visar att företrädesemissionen är övertecknad. Genom företrädesemissionen kommer Klövern att tillföras cirka 2 miljarder kronor före emissionskostnader. Det preliminära utfallet visar att 17 103 861 stamaktier av serie A och 186 435 270 stamaktier av serie B tecknades med stöd av teckningsrätter, motsvarande 98,6 procent av antalet erbjudna stamaktier av serie A respektive 98,7 procent av antalet erbjudna stamaktier av serie B. Därtill har tecknings